Citation:Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al 2014

Citation

Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014 Jul 20;32(21):2240-7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24687833.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Molecular pathology and biomarkers – implications for systemic therapy